CureVac is a German biopharmaceutical company developing mRNA-based vaccines and therapies for infectious diseases and cancer. Founded in 2000 in Tübingen, it built proprietary mRNA optimization, formulation and manufacturing technology. After a 2024 restructuring that cut roughly 30% of its workforce, CureVac was acquired by BioNTech in an all-stock exchange offer that closed in December 2025, and it now operates as a BioNTech subsidiary.
CureVac is publicly traded
IPO'd on Aug 14, 2020
This company is no longer available on our private secondary market. Shares can be traded publicly under CVAC.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2000
Employees
501–1,000
Total Funding
$810M
8 rounds
Last Private Valuation
$1.78B
Jul 20, 2020
Closed: BioNTech completed all-stock acquisition of CureVac via exchange offer, ~86.75% of shares tendered
Deal closed; CureVac equity converted to BioNTech ADSs, ending standalone secondary market
CureVac SE management board resigned as BioNTech closed its acquisition; Ugur Sahin, Sierk Poetting and Ramón Zapata-Gomez now form the board
Standalone CureVac leadership replaced by BioNTech executives
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $810M across 8 rounds
Last updated 09-16-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Jul 20, 2020 | Series B (GSK, QIA and other investors) | $297M | $1.78B | GlaxoSmithKline |
| Jun 15, 2020 | Series B (German Federal Government / KfW) | $339M | $1.47B | German Federal Government |
| Nov 8, 2016 | Series E Extension | $29.5M | — | Not disclosed |
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Entry · Series B (German Federal Government / KfW)
$1.5B
Jun 2020
CureVac today
$1.8B
Jul 2020 · latest mark
CureVac multiple
1.2x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
Ugur Sahin
Member of the Management Board, CureVac SE (CEO of BioNTech)
Sierk Poetting
Member of the Management Board, CureVac SE
Ramón Zapata-Gomez
Managing Director, CureVac Merger B.V.; Member of the Management Board, CureVac SE
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Moderna
US-based mRNA vaccine and therapeutic developer; leading mRNA market with 37.5% share as of 2024.
BioNTech
German mRNA vaccine and therapeutic platform company; now CureVac's parent company following December 2025 acquisition.
Arcturus Therapeutics
US-based biotech specializing in self-amplifying mRNA (saRNA) technology for infectious diseases and genetic disorders.
Yes, CureVac is publicly traded under the ticker symbol CVAC on the NASDAQ. The company went public in Aug 14, 2020.
CureVac trades under the ticker symbol CVAC on the NASDAQ. It began trading in Aug 14, 2020.
CureVac (CVAC on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker CVAC to place an order.
CureVac went public in Aug 14, 2020 via ipo, with an offering valuation of approximately $1.78B. CureVac listed on Nasdaq (CVAC) in August 2020 at $16 per share. BioNTech acquired it through an all-stock exchange offer that closed on December 18, 2025 with about 86.75% of shares tendered; the post-offer reorganization completed on January 6, 2026, making BioNTech the sole owner, and the shares were delisted from Nasdaq. In May 2026 BioNTech announced plans to close manufacturing sites including CureVac's former Tübingen headquarters.
CureVac raised $810M across 8 disclosed funding rounds prior to its public listing.
CureVac is headquartered in Tübingen, Germany.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.